Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17994247 | 0.95 | CCR1 (0.46) | FPR2ACEACE2KMT2A | |
| SCHEMBL16375211 | 0.93 | KMT2A (0.46) | FPR2ACEACE2KMT2AF10 | |
| SCHEMBL17994249 | 0.91 | PYGL (0.47) | ACEACE2KMT2A | |
| SCHEMBL17994246 | 0.89 | RAB9A (0.43) | FPR2F10 | |
| SCHEMBL16375209 | 0.87 | KMT2A (0.47) | ACEACE2KMT2A | |
| SCHEMBL17994250 | 0.84 | ACE (0.63) | ACEACE2TSHR | |
| SCHEMBL17994245 | 0.84 | HSPA1A (0.41) | KMT2A | |
| SCHEMBL16375215 | 0.83 | PYGL (0.48) | ACEACE2KMT2A | |
| SCHEMBL16375207 | 0.83 | RAB9A (0.43) | FPR2KMT2AF10MEN1 | |
| SCHEMBL17994253 | 0.80 | HSPA5 (0.43) | KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FPR2 492/4885ACE 3137/4885ACE2 3162/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FPR2 492/4885ACE 3137/4885ACE2 3162/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | FPR2 499/4885ACE 2924/4885ACE2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.